Clinical trial gives hope to patients with brain cancer

In a Phase 1 clinical trial, Queensland researchers have found that patients who received a cellular

immunotherapy for the deadly brain cancer glioblastoma multiforme (GBM) on average survived longer than would have been expected without the treatment.

/Public Release. The material in this public release comes from the originating organization and may be of a point-in-time nature, edited for clarity, style and length. View in full here.